PAHC$52.26
$52.36
Chart
Performance
Key Stats
AI PAHC Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyPhibro Animal Health Corporation shows strong fundamental performance and positive growth prospects. Technicals suggest a mixed short-term outlook, while thematic factors offer long-term stability.
Thematic
Operating in the animal health and mineral nutrition sector, Phibro benefits from steady demand for its products. However, it does not appear to be at the forefront of major disruptive technological themes.
Fundamental
Phibro Animal Health Corporation demonstrates strong profitability, consistent revenue growth, and a healthy balance sheet, with a notable dividend yield.
Technical
The stock is trading below key moving averages and oscillators suggest a neutral to slightly bearish momentum, indicating a need for caution in the short term.
| Factor | Score |
|---|---|
| Animal Health Market Growth | 75 |
| Mineral Nutrition Demand | 70 |
| Technological Disruption | 40 |
| Food Safety and Welfare Focus | 80 |
| Diversification | 60 |
| Factor | Score |
|---|---|
| Valuation | 45 |
| Profitability | 60 |
| Growth | 70 |
| Balance Sheet Health | 85 |
| Cash Flow | 80 |
| Dividends | 75 |
| Factor | Score |
|---|---|
| Trend Analysis | 40 |
| Momentum | 50 |
| Volume Confirmation | 55 |
| Support & Resistance | 65 |
| Oscillators | 70 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Strong Recent Performance
The stock has shown strong performance over various periods, with 1M performance at 27.78%, 6M at 43.28%, YTD at 48.67%, and 1Y at 67.19%.
Consistent Earnings Surprises
The company has consistently beaten earnings estimates, with surprises ranging from 6.9% to 41.7% over the last several quarters.
Bearish Points (7)
High P/E Ratio
The trailing P/E ratio of 39.12 is relatively high compared to some industry averages, which could indicate it's trading at a premium.
Slowing Revenue Growth
While annual revenue for 2024Q2 was $1.02 billion, the quarterly revenue for 2024Q2 was $273.16 million, a decrease from the previous quarter and showing lower net margin.
Calendar
June 2025
4
Ex-Dividend Date
June 2025
25
Next Dividend Date
August 2025
28
Next Earnings Date
H: $0.54
A: $0.52
L: $0.50
H: 367.00M
A: 362.24M
L: 357.48M
Profile
Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.
Seasonals
Price Target
23.50 USD
The 39 analysts offering 1 year price forecasts for PAHC have a max estimate of 26.00 and a min estimate of 19.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
The largest pure-play animal health company globally, offering a wide range of pharmaceuticals, vaccines, and diagnostic products for livestock and companion animals, making it a direct and primary competitor to PAHC.
Weight: 98
A leading global animal health company providing products and services to veterinarians, producers, pet owners, and others in more than 90 countries, directly competing with PAHC in various animal health segments.
Weight: 95
Operates a significant and comprehensive Animal Health division (Merck Animal Health) that develops, manufactures, and markets a broad range of veterinary pharmaceutical and vaccine products for livestock and companion animals, directly competing with PAHC.
Weight: 90
Although primarily known for pharmaceuticals and crop science, Bayer has an Animal Health business (integrated into its Crop Science division) that offers products for livestock and companion animals, positioning it as a competitor.